Alnylam Pharmaceuticals | ALNY - Capitale Ordinario





Capitale Ordinario Cambiamento Data
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
Agios Pharmaceuticals USD 59.34M 892K 2026-03
Alnylam Pharmaceuticals USD 133.44M 1.07M 2026-03
Amgen USD 540M 1000K 2026-03
Arrowhead Research USD 137.39M 1.69M 2025-12
BioCryst Pharmaceuticals USD 213.06M 2.54M 2025-12
BioMarin Pharmaceutical USD 193.27M 969K 2026-03
Incyte USD 199.95M 1.49M 2026-03
Ionis Pharmaceuticals USD 165.9M 3.93M 2026-03
Moderna USD 391M 2M 2025-09
Neurocrine Biosciences USD 100.6M 500K 2026-03
Novartis USD 1.91B 10.64M 2025-12
PTC Therapeutics USD 81.47M 1.54M 2025-12
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Sarepta Therapeutics USD 105.57M 607K 2026-03
Takeda JPY 1.58B 241K 2026-03
Tectonic Therapeutic USD 18.74M 25.03K 2025-12
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
Vertex Pharmaceuticals USD 254.2M 200K 2026-03
Xencor USD 74.06M 2.19M 2026-03